Sharp Quality Leader Advocates for Supply Chain-Wide Quality Culture Beyond Compliance

Grace Breen (搜索)搜索该词条, Senior Vice President of Quality at Sharp (搜索)搜索该公司, is reshaping how the pharmaceutical industry approaches quality management, advocating for a fundamental shift from compliance-focused oversight to supply chain-wide quality culture. With over 30 years of experience across CDMO, brand, and generic pharmaceutical sectors, Breen leads Sharp's global quality function through a Quality Management Maturity (搜索)搜索该靶点 (QMM) model designed to drive sustainable cGMP查看药品详情 compliance.

Quality Built Upstream, Not Inspected at the End

Breen's philosophy centers on a critical principle: "Quality is built upstream and throughout the supply chain, not inspected in at the end." This approach recognizes that every actor in the pharmaceutical supply chain—from active ingredient and component suppliers to contract laboratories, finished product manufacturers, contract packagers, and distributors—contributes to the quality of the finished drug product and ultimately patient outcomes.

"This principle has shaped my perspective on quality stewardship to be more than compliance and oversight—it is a leadership obligation to design, protect and strengthen quality across the supply chain to safeguard patient outcomes long before final inspection," Breen explained. She emphasizes that without a supply chain perspective, weak design and governance at any node become risk everywhere, reframing the supply chain as a single quality system.

Learning from Supply Chain Vulnerabilities

Breen's formative experiences highlighted how upstream vulnerabilities can have significant downstream consequences. In one case, inadequate oversight of a tier 2 supplier by the primary supplier led to a product defect that went undetected until customer complaints surfaced. Another example involved a seemingly minor change in API查看药品详情 particle size that went undetected by the drug product manufacturer, adversely impacting the dissolution profile and disrupting supply while limiting patient access to vital medication.

"Early experiences like these informed my knowledge of the complex web that creates quality," Breen noted. "I learned to look more broadly beyond the immediate failure, to understand where system vulnerabilities may exist and why they matter." These learnings proved essential as she navigated increasing drug and supply chain complexity, heightened regulatory scrutiny, and rising customer expectations in leadership roles.

Empowering Frontline Insight and Intuition

A key component of Breen's quality philosophy involves trusting frontline operators and cultivating pattern recognition abilities. She learned that production operators are often the first to notice subtle anomalies that are not yet measurable, making their empowerment crucial for fostering personal ownership and accountability for quality.

"Empowering them to speak up when something 'feels wrong' fosters personal ownership and accountability for quality, strengthening compliance, and improving outcomes," Breen explained. While emphasizing that intuition must complement rather than replace data-driven decision-making, she advocates for using intuitive insights to prompt deeper investigations when data is incomplete, delayed, or overly narrow.

Beyond Compliance: Quality as Business Driver

Breen's perspective evolved from viewing quality as mere compliance to recognizing it as a driver of excellence, value, and business success. She observed that companies often struggled with rework, delays, and recurring deviations despite passing regulatory inspections, leading to her realization that compliance alone did not equal quality.

"True quality emerged when processes were intentionally designed to enable 'right the first time', reducing errors, accelerating release timelines, and improving predictability for the business," she stated. "Compliance becomes the foundation; operational excellence becomes the differentiator."

A particularly instructive experience involved supplier selection where cost was prioritized once regulatory requirements were met, but process capability and system maturity were underestimated. The downstream effects included poor process control, prolonged investigations, unreliable supply, drug shortages, and erosion of customer confidence. This reinforced her principle that "compliance will get you into the system, quality determines whether the system performs."

Quality Leadership as Business Leadership

Breen's field experiences visiting hospital pharmacies with sales colleagues provided real-world perspective on drug shortages' impact on patients and caregivers. These moments made quality personal and reinforced her conviction that right-first-time execution and uninterrupted supply represent commitments to patients, customers, and colleagues rather than merely operational goals.

"When quality is treated as a business and leadership discipline, not just a functional requirement, it does far more than prevent errors," Breen observed. "It shapes how work gets done every day—reducing waste, creating space for innovation, and building systems that perform consistently and endure over time."

While quality may not directly generate revenue, Breen emphasizes its undeniable business value in protecting revenue streams, enabling speed-to-market, reducing risk, safeguarding a company's license to operate, and preserving trust with customers and regulators. Through her experiences, she has learned that leading quality is inseparable from leading the business itself, requiring strategic thinking, sustainable performance focus, and responsibility for shaping organizational future.

The interview represents Part 1 of a series, with Part 2 set to cover the five phases involved in a pharmaceutical company or CDMO's evolution to a mature Pharmaceutical Quality System (搜索)搜索该靶点 (PQS) framework.